IIIBIV期经治非小细胞肺癌患者中进
点击下方，收听SCI天天读57Arandomized,double-blind,placebo-controlled,phaseIIItrialoferlotinibwithorwithoutac-Metinhibitortivantinib(ARQ)inAsianpatientswithpreviouslytreatedstageIIIB/IVnonsquamousnonsmall-celllungcancerharboringwild-typeepidermalgrowthfactorreceptor(ATTENTIONstudy).BACKGROUNDApreviousrandomizedphaseIIstudydemonstratedthattheadditionofac-Metinhibitortivantinibtoanepidermalgrowthfactorreceptor(EGFR)tyrosinekinaseinhibitorerlotinibmightprolongprogression-freesurvival(PFS)inpatientswithpreviouslytreated,nonsquamousnonsmall-celllungcancer(NSCLC).Onasubsetanalysis,thesurvivalbenefitwasgreaterinpatientswithwild-typeEGFR(WT-EGFR)thaninthosewithactivatingEGFRmutations.Herein,thisphaseIIIstudy北京白癜风医院哪个好专业白癜风品牌
